Clinical Trials
8 trialsNCT02954523 2024-07-05
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Georgetown University
Phase 1/2 Terminated
NCT01514864 2023-12-19
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
Bristol-Myers Squibb
Phase 2 Terminated
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00459342 2019-03-05
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00787267 2016-06-30
TOP0801
Duke University
Phase 2 Terminated
NCT00826449 2016-06-28
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00570401 2016-01-22
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00564876 2015-02-23
TOP0706
Duke University
Phase 2 Terminated